2015 American Transplant Congress
Treatment With Everolimus and Reduced-Exposure Cyclosporine Is Efficacious in De Novo Renal Transplant Recipients at Increased Risk for Efficacy Failure: Post-Hoc Analysis from the A2309 Study
1For the A2309 Study Group, Italy; 2Novartis, Basel, Switzerland.
Purpose: Data is limited on the effect of everolimus (EVR) based regimens in renal transplant recipients (RTxR) who are at increased risk for rejection and…2015 American Transplant Congress
Factors Affecting Efficacy Outcomes at 12 and 24-Months After Kidney Transplantation in Patients from the A2309 Study
1Novartis, Basel, Switzerland; 2A2309 Study Group, Basel, Switzerland; 3Novartis, East Hanover, NJ.
Purpose: Efficacy outcomes post-transplantation are influenced by donor and recipient variables and interactions between them. Here, we present data from a multivariate analysis of risk…2015 American Transplant Congress
Electronic Health Service to Improve Therapeutic Drug Monitoring of Immunosuppressants
PurposeTherapeutic drug monitoring (TDM) of immunosuppressants is critical to avoid rejection or toxic side effects by under- or over-immunosuppression after heart transplantation (HTx). Hence, in…2015 American Transplant Congress
Efficacy of Low Dose Chemoprophylaxis for Coccidioidomycosis Infection in Liver Transplantation Recipients
Introduction:Coccidioidomycosis(CM) infection rate of 6.9% has been reported in solid organ transplantation recipients living in endemic Southwestern U.S.Aim:Assess the risk of CM infection in liver…2015 American Transplant Congress
Targeting Complement Pathways During Ischemia and Reperfusion: Implications for the Prevention of Delayed Graft Function
Complement system plays a critical role in ischemia-reperfusion injury (IRI), and contributes to DGF. The aim of this study was to evaluate the effects of…2015 American Transplant Congress
Early Conversion to Everolimus in De Novo Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study
For the ELEVATE Study, Leiden, Netherlands.
Purpose: Long-term exposure to calcineurin inhibitors (CNIs) contributes to unfavorable long-term outcomes, including inferior renal function and premature graft loss with vascular lesions, glomerulosclerosis and…2015 American Transplant Congress
Everolimus and Early Calcineurin Inhibitor Withdrawal Is Associated With Superior Renal Function: 5-Year Follow-Up of the Randomized PROTECT Liver Transplantation Study
PROTECT Study Group, Novartis Pharma GmbH, Germany.
Purpose: At the end of the 12-month (M) PROTECT core study (NCT00378014), de novo liver transplant recipients (LTxR) who switched from a calcineurin inhibitor (CNI)…
- « Previous Page
- 1
- …
- 12
- 13
- 14